The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.
 
Feng Bi
No Relationships to Disclose
 
Shukui Qin
No Relationships to Disclose
 
Shanzhi Gu
No Relationships to Disclose
 
Yuxian Bai
No Relationships to Disclose
 
Zhendong Chen
No Relationships to Disclose
 
Zishu Wang
No Relationships to Disclose
 
Jieer Ying
No Relationships to Disclose
 
Yinying Lu
No Relationships to Disclose
 
Zhiqiang Meng
Research Funding - Bristol-Myers Squibb
 
Hongming Pan
No Relationships to Disclose
 
Ping Yang
No Relationships to Disclose
 
Helong Zhang
No Relationships to Disclose
 
Xi Chen
No Relationships to Disclose
 
Aibing Xu
No Relationships to Disclose
 
Xiufeng Liu
No Relationships to Disclose
 
Qiu Meng
No Relationships to Disclose
 
Liqing Wu
Employment - Suzhou Zelgen Biopharmaceuticals
Leadership - Suzhou Zelgen Biopharmaceuticals
Stock and Other Ownership Interests - Suzhou Zelgen Biopharmaceuticals
 
Feng Chen
No Relationships to Disclose